Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients
April 30, 2020 at 08:00 AM EDT
Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus.
